Biotech catalyst, news and analysis PDUFA tracker
Memory-to-optics rotation and the draft US ban on Chinese modules: Ciena at $1.57B revenue, Lumentum at a 47.9% gross margin, POET at half a million with warrants struck at $26.25.
ADMA has repurchased about 13.8 million shares in 2026 while ASCENIV keeps growing, gross margin remains near 70%, short interest stays elevated and retail discussion has shifted toward State Street, a possible squeeze, SG-001 and buyout speculation. The useful question is not whether these narratives sound bullish. It is which ones actually change per-share value — and which ones do not.
Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland.
A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington.
Six verified biotech developments published today: an accepted rare-disease NDA, updated PCNSL response data, the opening of a rolling Wilson-disease application, a positive brain-metastases imaging study, a Canadian ALS regulatory path and a $1.5 billion cell-therapy tools acquisition.
The July 13–17 tape delivered a sharp semiconductor reset, cooler inflation data, a renewed oil shock and resilient rotation below the headline indices. Next comes Alphabet, Tesla, Texas Instruments and Intel, plus AMD’s AI event, Farnborough, biotech data and a weekend FDA decision.
A U.S.-only defense report covering traditional primes, scaled defense-tech, high-beta drone and AI names, and national-security space companies already followed by Merlintrader. The central question is not whether military demand exists, but which companies can turn budgets and contract ceilings into funded backlog, margins and free cash flow per share.
The space economy has not stopped growing, but its public-market proxies have lost scarcity, absorbed a wave of new securities and broken key technical support. This report separates the common sector shock from each company’s own risks and identifies what would have to change before the decline can credibly reverse.
Jasper has acquired Kira Pharmaceuticals and preserved its Nasdaq ticker, but the company behind that ticker is being rebuilt around Kira’s complement pipeline. The financing solves an immediate liquidity crisis; the ownership math leaves legacy Jasper holders with only 6.68% of the combined company and creates a capital structure that will almost certainly require further corporate action.
The AI boom is no longer only a semiconductor and cloud-computing story. It is becoming a race for mission-ready software, deployable electricity and secure magnet supply. This report separates the common narrative from the very different financial realities of BigBear.ai, Bloom Energy and MP Materials.
Space Economy · $ASTS · $RKLB · $SPCE · $FJET Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and…
ARQT, LNTH and UNCY face FDA target action dates on June 29, while VRDN follows on June 30. The setup spans pediatric dermatology, nuclear medicine imaging, dialysis-related nephrology and thyroid eye disease — four very different regulatory events with very different trading profiles.
Report date: June 25, 2026
Financial data: latest Q1 2026 updates where available
A short squeeze does not happen just because a stock is “heavily shorted.” It happens when many short sellers need to exit at the same time, on a tight float, with volume accelerating and a catalyst strong enough to change the story. INR, SNSE and WOLF show three different versions of the same risk.
Karyopharm is heading into ASCO 2026 with one of the more debate-friendly biotech setups of the week: a Phase 3 myelofibrosis trial that hit spleen-volume reduction, missed its symptom co-primary endpoint, showed a company-described promising survival signal, and may still feed into an FDA discussion for a possible sNDA path.
The week ended May 1 kept the bullish market structure alive. U.S. equities came out of an earnings-heavy stretch with the S&P 500 and Nasdaq still pressing record levels, helped by strong corporate results, renewed confidence around AI infrastructure spending and a late-week easing in crude oil pressure. The market entered May with momentum, and that matters because the old “sell in May” warning is not enough by itself to override a tape that still has earnings, flows and leadership behind it.
Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.
Positive GLOW2 topline data do more than add one more green headline to the tape. They materially strengthen the diabetic retinopathy package around Zenkuda, reduce the “one-study wonder” risk left after GLOW1, and push the KOD debate toward the next question that really matters: how much value the market should assign to a program that now looks BLA-ready across multiple retinal settings, while still carrying the memory of earlier setbacks and the need to deliver again in DAYBREAK.
Next Catalyst / Prossimo catalyst: March 30, 2026 Nasdaq compliance deadline on the stockholders’ equity rule, based on the company’s disclosed panel extension. EN / IT toggle inside the content area, with mirrored sections. EN IT Artelo Biosciences (ARTL) —…
